• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

Ensuring continuity of Pharmacovigilance activities in a COVID pandemic

05.08.2021/in Publications /by Marketing

At the end of 2019, humanity faced a new coronavirus infection that swept across all continents and became a pandemic in a short period. This circumstance has led to forced restrictions on human contact and decreased productivity in many industries. Changes have also occurred in the provision of pharmacovigilance processes.

 Regardless of the world situation, a company’s routine pharmacovigilance processes include interacting with health care providers and patients, collecting information about adverse reactions, maintaining a database of those reactions, determining the signal, analyzing information, reporting data, providing periodic reports, and more. Internally, these functions are regulated by regulations, job descriptions, and standard operating procedures. If the pharmacovigilance system processes are well structured, there should be no difficulties in collecting information and reporting data in a pandemic environment. For X7 Research, we decided to increase our vigilance in handling incoming reports and pay special attention to those adverse reactions that are similar to the symptoms of COVID-19 infection. We also effectively ensure continuity of pharmacovigilance processes even in the face of emerging constraints. All incoming adverse reactions are coded with a MedDRA medical dictionary, which allows processing large amounts of data and quickly identifying emerging “trends” among the received information. There is also a convenient system of interaction with regulatory authorities for reporting adverse reactions through the Pharmacovigilance Automated Information System online in Russia.

 Globally, ensuring the safe use of medicines is a priority for modern healthcare. During an outbreak of viral infection, anyone will try to protect themselves and their loved ones by following preventive measures. These include frequent hand washing, use of antiseptics and disinfectants, taking vitamins, etc. In this case, pharmacovigilance specialists must be prepared for a possible increase in reports of adverse reactions. This hypothesis can be easily tested. The World Health Organization recommends the use of alcohol-based hand sanitizers, which rarely cause adverse reactions when used routinely. This is confirmed by previously published data in the FAERS (The FDA Adverse Event Reporting System) open database, where all “alcohol-based sanitizer” queries have hardly 20 adverse reactions. However, a recently published study from the epicenter of China, in which healthcare workers treated their hands with alcohol-based antiseptics more than 10 times a day, reported that of 321 healthcare workers, 76.6% developed hand skin lesions and dermatitis symptoms. The high incidence of skin adverse reactions is at least of scientific interest and provides new information about the safety of these agents. And for manufacturers, these data can serve as a reason to change precautions in the use of skin antiseptics.

 If in the previous example we cannot draw any conclusions and the data were provided only for thought, the following information is already a scientifically documented fact. For previously unknown diseases, taking any medication is “off-label,” that is, not for the indications given in the instructions for medical use. Due to the high incidence of COVID-19, the Solidarity clinical trial (more than 3,500 patients from 35 countries) was launched to find drugs to treat this infection. One of the objectives was to study the therapeutic efficacy of a hydroxychloroquine-based drug. After some time in the study, on May 23, 2020, the Solidarity executive team made an official announcement of its decision to suspend the study of hydroxychloroquine due to negative safety data on the drug. The Data Monitoring and Analysis Committee (this is the role of pharmacovigilance in clinical trials) conducted an analysis and reacted instantly in a way that would minimize risks and keep trial participants safe [2]. Each report of a suspected adverse reaction contributes to an up-to-date view of a drug’s safety profile. By the way, after a thorough evaluation of all adverse events and deaths, the hydroxychloroquine study has resumed, and the safety data monitoring and analysis committee continues to closely monitor the study.

Each of these examples involves huge resources, ensuring continuity of pharmacovigilance both at the global level and at the level of pharmacovigilance of a specific company. The performance of any system is determined by its ability to adapt to current conditions. Maintaining a heightened focus on reported adverse reactions and doing their job well are some of the key requirements for pharmacovigilance in a pandemic.

 

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Corrections to clinical trial documents due to COVID-19. Russian experience.
Read More
Publications
WHAT IS BIOEQUIVALENCE
Read More
Publications
THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 1 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
How to increase patient and health care provider awareness of diseases? Russian... Important modifications in pharmacovigilance of the EAEU in 2017
Scroll to top